Open AccessImpact of FcγR variants on the response to alemtuzumab in multiple sclerosis
Author(s) -
Keller Christian W.,
Ruck Tobias,
McHugh Donal,
Pfeuffer Steffen,
Gross Catharina C.,
Korsukewitz Catharina,
Melzer Nico,
Klotz Luisa,
Meuth Sven G.,
Münz Christian,
Nimmerjahn Falk,
Wiendl Heinz,
Lünemann Jan D.
Publication year - 2019
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.50935
Subject(s) - alemtuzumab , medicine , multiple sclerosis , immunology , allele , gene , oncology , antibody , genetics , biology
Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell‐depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high‐affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing‐remitting multiple sclerosis. No differences in clinical and MRI‐based efficacy parameters, the development of severe infusion‐associated reactions and secondary autoimmune diseases during a 2 year follow‐up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.